Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial
December 23, 2024 08:30 ET
|
Vivos Inc.
Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India....
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
October 18, 2024 08:30 ET
|
Vivos Inc.
Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty...
Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics
September 30, 2024 08:30 ET
|
Vivos Inc.
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable...
Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA
July 29, 2024 08:30 ET
|
Vivos Inc.
Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update The FDA has been working diligently to review the extensive amount of...
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
June 28, 2024 10:15 ET
|
Vivos Inc.
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing...
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
December 20, 2023 10:08 ET
|
Vivos Inc.
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy...
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
January 11, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision...
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
January 03, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision...
Vivos Inc Files a New Patent on the Hydrogel Component of IsoPet®/RadioGel™
September 14, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA...
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy
August 16, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer...